Utilizing Conversational Artificial Intelligence, Voice, and Phonocardiography Analytics in Heart Failure Care.

Conversational artificial intelligence involves the ability of computers, voice-enabled devices to interact intelligently with the user through voice. This can be leveraged in heart failure care delivery, benefiting the patients, providers, and payers, by providing timely access to care, filling the gaps in care, optimizing management, improving quality of care, and reducing cost. Introduction of machine learning to phonocardiography has potential to achieve outstanding diagnostic and prognostic performances in heart failure patients. There is ongoing research to use voice as a biomarker in heart failure patients. If successful, this may facilitate the screening, diagnosis, and clinical assessment of heart failure.

Investigating voice as a biomarker: Deep phenotyping methods for early detection of Parkinson's disease.

Voice technology has grown tremendously in recent years and using voice as a biomarker has also been gaining evidence. We demonstrate the potential of voice in serving as a deep phenotype for Parkinson's Disease (PD), the second most common neurodegenerative disorder worldwide, by presenting methodology for voice signal processing for clinical analysis. Detection of PD symptoms typically requires an exam by a movement disorder specialist and can be hard to access and inconsistent in findings. A vocal digital biomarker could supplement the cumbersome existing manual exam by detecting and quantifying symptoms to guide treatment. Specifically, vocal biomarkers of PD are a potentially effective method of assessing symptoms and severity in daily life, which is the focus of the current research. We analyzed a database of PD patient and non-PD subjects containing voice recordings that were used to extract paralinguistic features, which served as inputs to machine learning models to predict PD severity. The results are presented here and the limitations are discussed given the nature of the recordings. We note that our methodology only advances biomarker research and is not cleared for clinical use. Specifically, we demonstrate that conventional machine learning models applied to voice signals can be used to differentiate participants with PD who exhibit little to no symptoms from healthy controls. This work highlights the potential of voice to be used for early detection of PD and indicates that voice may serve as a deep phenotype for PD, enabling precision medicine by improving the speed, accuracy, accessibility, and cost of PD management.

Readiness for Voice Technology in Patients With Cardiovascular Diseases: Cross-Sectional Study.

BACKGROUND: The clinical application of voice technology provides novel opportunities in the field of telehealth. However, patients' readiness for this solution has not been investigated among patients with cardiovascular diseases (CVD). OBJECTIVE: This paper aims to evaluate patients' anticipated experiences regarding telemedicine, including voice conversational agents combined with provider-driven support delivered by phone. METHODS: A cross-sectional study enrolled patients with chronic CVD who were surveyed using a validated investigator-designed questionnaire combining 19 questions (eg, demographic data, medical history, preferences for using telehealth services). Prior to the survey, respondents were educated on the telemedicine services presented in the questionnaire while being assisted by a medical doctor. Responses were then collected and analyzed, and multivariate logistic regression was used to identify predictors of willingness to use voice technology. RESULTS: In total, 249 patients (mean age 65.3, SD 13.8 years; 158 [63.5%] men) completed the questionnaire, which showed good repeatability in the validation procedure. Of the 249 total participants, 209 (83.9%) reported high readiness to receive services allowing for remote contact with a cardiologist (176/249, 70.7%) and telemonitoring of vital signs (168/249, 67.5%). The voice conversational agents combined with provider-driven support delivered by phone were shown to be highly anticipated by patients with CVD. The readiness to use telehealth was statistically higher in people with previous difficulties accessing health care (OR 2.920, 95% CI 1.377-6.192) and was most frequent in city residents and individuals reporting a higher education level. The age and sex of the respondents did not impact the intention to use voice technology (P=.20 and P=.50, respectively). CONCLUSIONS: Patients with cardiovascular diseases, including both younger and older individuals, declared high readiness for voice technology.

Capturing At-Home Health and Care Information for Children With Medical Complexity Using Voice Interactive Technologies: Multi-Stakeholder Viewpoint.

Digital health tools and technologies are transforming health care and making significant impacts on how health and care information are collected, used, and shared to achieve best outcomes. As most of the efforts are still focused on clinical settings, the wealth of health information generated outside of clinical settings is not being fully tapped. This is especially true for children with medical complexity (CMC) and their families, as they frequently spend significant hours providing hands-on medical care within the home setting and coordinating activities among multiple providers and other caregivers. In this paper, a multidisciplinary team of stakeholders discusses the value of health information generated at home, how technology can enhance care coordination, and challenges of technology adoption from a patient-centered perspective. Voice interactive technology has been identified to have the potential to transform care coordination for CMC. This paper shares opinions on the promises, limitations, recommended approaches, and challenges of adopting voice technology in health care, especially for the targeted patient population of CMC.

Artificial Intelligence in Cardiology-A Narrative Review of Current Status.

Artificial intelligence (AI) is an integral part of clinical decision support systems (CDSS), offering methods to approximate human reasoning and computationally infer decisions. Such methods are generally based on medical knowledge, either directly encoded with rules or automatically extracted from medical data using machine learning (ML). ML techniques, such as Artificial Neural Networks (ANNs) and support vector machines (SVMs), are based on mathematical models with parameters that can be optimally tuned using appropriate algorithms. The ever-increasing computational capacity of today's computer systems enables more complex ML systems with millions of parameters, bringing AI closer to human intelligence. With this objective, the term deep learning (DL) has been introduced to characterize ML based on deep ANN (DNN) architectures with multiple layers of artificial neurons. Despite all of these promises, the impact of AI in current clinical practice is still limited. However, this could change shortly, as the significantly increased papers in AI, machine learning and deep learning in cardiology show. We highlight the significant achievements of recent years in nearly all areas of cardiology and underscore the mounting evidence suggesting how AI will take a central stage in the field.

Feasibility of Incorporating Voice Technology and Virtual Assistants in Cardiovascular Care and Clinical Trials.

PURPOSE OF REVIEW: With the rising cost of cardiovascular clinical trials, there is interest in determining whether new technologies can increase cost effectiveness. This review focuses on current and potential uses of voice-based technologies, including virtual assistants, in cardiovascular clinical trials. RECENT FINDINGS: Numerous potential uses for voice-based technologies have begun to emerge within cardiovascular medicine. Voice biomarkers, subtle changes in speech parameters, have emerged as a potential tool to diagnose and monitor many cardiovascular conditions, including heart failure, coronary artery disease, and pulmonary hypertension. With the increasing use of virtual assistants, numerous pilot studies have examined whether these devices can supplement initiatives to promote transitional care, physical activity, smoking cessation, and medication adherence with promising initial results. Additionally, these devices have demonstrated the ability to streamline data collection by administering questionnaires accurately and reliably. With the use of these technologies, there are several challenges that must be addressed before wider implementation including respecting patient privacy, maintaining regulatory standards, acceptance by patients and healthcare providers, determining the validity of voice-based biomarkers and endpoints, and increased accessibility. SUMMARY: Voice technology represents a novel and promising tool for cardiovascular clinical trials; however, research is still required to understand how it can be best harnessed.

Depression Screening from Voice Samples of Patients Affected by Parkinson's Disease.

Depression is a common mental health problem leading to significant disability world wide. Depression is not only common but also commonly co-occurs with other mental and neurological illnesses. Parkinson's Disease gives rise to symptoms directly impairing a person's ability to function. Early diagnosis and detection of depression can aid treatment, but diagnosis typically requires an interview with a health provider or structured diagnostic questionnaire. Thus, unobtrusive measures to monitor depression symptoms in daily life could have great utility in screening depression for clinical treatment. Vocal biomarkers of depression are a potentially effective method of assessing depression symptoms in daily life, which is the focus of the current research. We have a database of 921 unique patients with Parkinson's disease and their self assessment of whether they felt depressed or not. Voice recordings from these patients were used to extract paralinguistic features, which served as inputs to machine-learning and deep learning techniques to predict depression. The results are presented here and the limitations are discussed given the nature of the recordings which lack language content. Our models achieved accuracies as high as 0.77 in classifying depressed and non-depressed subjects accurately using their voice features and PD severity. We found depression and severity of Parkinson's Disease had a correlation coefficient of 0.3936, providing a valuable feature when predicting depression from voice. Our results indicate a clear correlation between feeling depressed and the severity of the Parkinson's disease. Voice may be an effective digital biomarker to screen for depression among patients suffering from Parkinson's Disease.